共 50 条
- [1] Safety and antitumor activity from the phase lb study of ramucirumab plus pembrolizumab in treatment-naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)[J]. ANNALS OF ONCOLOGY, 2019, 30 : 122 - 122Chau, I.Bendell, J.Soriano, A.Arkenau, H.Cultreras, J.Santana-Davila, R.Calvo, E.Le Toumeau, C.Zender, L.Mi, G.Schelman, W.Ferry, D.Herbst, R.Fuchs, C.
- [2] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Chau, IanBendell, Johanna C.Calvo, Emiliano-Davila, Rafael SantanaArkenau, Hendrik-TobiasMi, GuJin, JinRege, JessiccaFerry, DavidHerbst, Roy S.Fuchs, Charles S.
- [3] Safety and efficacy of ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: a multi-disease phase 1 study[J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 255Thuss-Patience, P.Vasile, E.Chau, IPenel, N.Mi, G.Emig, M.Fuchs, C. S.
- [4] Ramucirumab in Combination with Pembrolizumab in Treatment-Naive Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial[J]. CANCERS, 2020, 12 (10) : 1 - 16Chau, IanPenel, NicolasSoriano, Andres O.Arkenau, Hendrik-TobiasCultrera, JenniferSantana-Davila, RafaelCalvo, EmilianoLe Tourneau, ChristopheZender, LarsBendell, Johanna C.Mi, GuGao, LingMcNeely, Samuel ClarkOliveira, Joana M.Ferry, DavidHerbst, Roy S.Fuchs, Charles S.
- [5] Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Chau, IanBendell, Johanna C.Calvo, EmilianoSantana-Davila, RafaelAhnert, Jordi RodonPenel, NicolasArkenau, Hendrik-TobiasYang, JingRege, JessiccaMi, GuFerry, DavidHerbst, Roy S.Fuchs, Charles S.
- [6] Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)Bang, Yung-JueGolan, TaliaLin, Chia-ChiKang, Yoon-KooWainberg, Zev A.Wasserstrom, HeatherJin, JinMi, GuMcNeely, SamuelLaing, NaomiGoff, Laura WilliamsFu, Siqing
- [7] A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma[J]. ANNALS OF ONCOLOGY, 2017, 28Talia, GolanLin Chia-ChiFu SiqingHeather, WasserstromMi GuNaomi, LaingMaria, KarasaridesYung-Jue, Bang
- [8] Phase I study to evaluate the safety, tolerability and preliminary efficacy of rivoceranib plus paclitaxel in advanced gastric or gastroesophageal junction (GEJ) cancer[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1114 - S1114Ryu, M. H.Pande, A.Kim, J. H.Kang, Y-K.
- [9] A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Herbst, Roy S.Bendell, Johanna C.Isambert, NicolasCalvo, EmilianoSantana-Davila, RafaelCassier, PhilippePerez-Gracia, Jose LuisYang, JingRege, JessiccaFerry, DavidMi, GuChau, Ian
- [10] Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data[J]. ANNALS OF ONCOLOGY, 2017, 28Herbst, R. S.Martin-Liberal, J.Calvo, E.Isambert, N.Bendell, J.Cassier, P.Jin, J.Mi, G.Rege, J.Paz-Ares, L.